CRISPR Therapeutics–Citigroup: investor conference, 201712 supply service 1-on-1 meetings at Citi Global Healthcare Conference NY

	Period	2017-12-06
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Partner, 2nd	Citigroup (Group)
	Product	Citi Global Healthcare Conference 2017 New York
	Product 2	CRISPR gene editing technology
	Person	Brinzey, Christopher F. (Chris) (Westwicke Partners 201703)
	Person 2	Erdman, Chris (CRISPR Therapeutics 201711 Investor Relations)

CRISPR Therapeutics AG. (11/28/17). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA.

CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present or host one-on-one meetings at five upcoming Investor Conferences.

29th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 29, 2017
Fireside Chat: 1:00-1:25 PM ET

Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 30, 2017
Presentation: 3:00-3:20 PM ET
Panel Discussion: 3:40-4:40 PM ET Gene Editing: Putting Molecular Scissors in Real Life Use

Evercore ISI BioPharma Catalyst/Deep Dive Conference
Date: Thursday, November 30, 2017
Fireside Chat: 10:15-10:35 AM ET

Citi 2017 Global Healthcare Conference
Date: Wednesday December 6, 2017
One-on-one meetings only

Guggenheim 4th Annual Boston Healthcare Conference
Date: Tuesday December 13, 2017
One-on-one meetings only

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Erdman
+1 617.307.7227 chris.erdman@crisprtx.com

Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com